2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2364

Vasculitis Patient Journey: A Scoping Review of Patient Experiences with Vasculitis

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2721

Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2337

Vertebral Compression Fractures and Antibodies to Citrullinated Vimentin in Established Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: L07

VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2454

Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2330

Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2241

What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2693

What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2227

What Should be the Goals of Gout Therapy? a Patient Perspective

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2375

When Are People Receptive to Self Management Education Information, and What Information Appeals to Them? : An Analysis of Digital Data

Patient Outcomes, Preferences, and Attitudes Poster II – ARHP

9:00AM-11:00AM: Abstract Number: 2477

Which Is the Best Measure for Rheumatoid Arthritis Disease Activity? a Head to Head Comparison of the Six American College of Rheumatology Recommended Disease Activity Measures

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2027

Whole Exome Trio Sequencing Implicates DOCK2 in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2468

Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2177

Workforce Requirements in Rheumatology: A Systematic Literature Reviewinforming the Development of a Workforce Prediction Risk of Bias Tool and the EULAR Points to Consider

Health Services Research Poster III – ACR/ARHP

11:00AM-12:30PM: Abstract Number: 2787

−21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)

5T046 ACR Abstract: Plenary Session III (2785–2790)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].